Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study

BACKGROUND/AIMS: Infliximab (IFX) has been used to induce and maintain remission in patients with severe steroid-refractory ulcerative colitis (UC). Long-term use of biologics in developing countries is limited by high cost and frequent side effects. An optimal maintenance strategy in these patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahajan, Ramit, Singh, Arshdeep, Kedia, Saurabh, Kaur, Kirandeep, Midha, Vandana, Sahu, Pabitra, Mehta, Varun, Singh, Dharmatma, Bansal, Namita, Dharni, Khushdeep, Kaushal, Sandeep, Ahuja, Vineet, Sood, Ajit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831781/
https://www.ncbi.nlm.nih.gov/pubmed/33525859
http://dx.doi.org/10.5217/ir.2020.00100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831781/
https://www.ncbi.nlm.nih.gov/pubmed/33525859
http://dx.doi.org/10.5217/ir.2020.00100

Ejemplares similares